Dublin, June 26, 2019 (GLOBE NEWSWIRE) -- The "Global Pomalyst (Celgene) Drug Overview & Product Profiles Report 2017-2026 with Sales by Country" report has been added to ResearchAndMarkets.com's offering.

Pomalyst (pomalidomide; Celgene) is an oral class I thalidomide analog, immunomodulatory drug with antineoplastic activity.

In vitro studies have shown that the drug acts through multiple mechanisms. Evidence suggests that in addition to anti-angiogenic effects, Pomalyst inhibits proliferation and induces apoptosis of hematopoietic tumor cells, and may have antineoplastic effects.

Pomalyst also enhanced T cell- and natural killer cell-mediated immunity and inhibited production of pro-inflammatory cytokines by monocytes.

Key Topics Covered

1. Drug Overview
2. Product Profiles
3. Pomalyst : Multiple myeloma

LIST OF FIGURES
Figure 1: Pomalyst for multiple myeloma - SWOT analysis
Figure 2: The authors drug assessment summary of Pomalyst for multiple myeloma
Figure 3: The authors drug assessment summary of Pomalyst for multiple myeloma
Figure 4: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES
Table 1: Pomalyst drug profile
Table 2: Pomalyst pivotal trial data in multiple myeloma
Table 3: Pomalyst late-phase trial data in multiple myeloma
Table 4: Pomalyst key ongoing clinical trials in multiple myeloma
Table 5: Pomalyst sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 6: Patients treated with Pomalyst across the US, Japan, and five major EU markets, by country, 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/bi5brg

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.